Mersana Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2005)

Organization Overview

First Clinical Trial
2010
NCT01011972
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Mersana Therapeutics | Mersana Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

xmt-1536 (2 trials)

xmt-1592 (1 trial)

Drugs in Phase 1 Trials (5)

xmt-1001 (1 trial)

xmt-1107 (1 trial)

xmt-1522 (1 trial)

xmt-1660 (1 trial)

xmt-2056 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Lung Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Ovarian Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 8